Document text
Principal Investigator: OFER LEVY
Organization: BOSTON CHILDREN'S HOSPITAL
Fiscal Year: 2020
Award: $184,957
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY:
From a cluster of respiratory illnesses in Wuhan, China, to a worldwide pandemic, the world has learned of a
novel coronavirus (SARS-CoV-2) but little is known about the pathogenesis that leads to the disease termed
“COVID”. Patients with SARS-CoV-2 infection range from asymptomatic, mild, moderate, to severe infections,
resulting in ICU hospitalization and even death. In the US alone, there is a prediction of ~100,000 – 240,000
deaths from SARS-CoV-2 infections. There is an urgent need to immunophenotype patients with COVID to
define biomarkers of disease severity and outcome to inform new interventions to prevent or treat this deadly
disease.
Key to characterizing the human immune response to SARS-CoV-2, is recruitment , enrollment and
retention of a cohort of study participants with COVID. To this end, we will employ best practices in clinical
research to pursue three Specific Aims (SAs). In SA1, we will recruit and enroll a well-defined cohort of adults
with SARS-CoV-2 (COVID-19); in SA2, we will obtain and store biosamples from patients in this COVID-19
cohort in support the NIAID immunophenotyping effort and in SA3 we will partner with the Clinical & Data
Coordinating Center (CDCC) to provide clinical data from this COVID-19 cohort to ensure these samples are
highly annotated with key clinical data.
Overall, successful pursuit of these SAs will provide well defined clinical samples and high quality
clinical data to support the NIAID COVID immunophenotyping effort.
Terms: <18 year old><18 years of age><2019 novel coronavirus><2019-nCoV><21+ years old><Address><Adult><Adult Human><Biological Markers><Blood><Blood Reticuloendothelial System><Boston><COVID><COVID-19><COVID19><Cessation of life><China><Clinical><Clinical Data><Clinical Research><Clinical Study><CoV disease><CoV emergence><Cohort Studies><Collection><Concurrent Studies><Coronaviridae><Coronavirus><Data Coordinating Center><Data Coordination Center><Death><Disease><Disease Outcome><Disorder><Enrollment><Ensure><Goals><Hospital Admission><Hospitalization><Hospitals><Human><IRB><IRBs><Immune response><Immunologic Subtyping><Immunological response><Immunophenotyping><Infection><Institutional Review Boards><Intervention><Intervention Strategies><Lead><Mainland China><Modern Man><NIAID><National Institute of Allergy and Infectious Disease><Outcome><Participant><Pathogenesis><Patients><Pb element><Pneumonia><Public Health><R-Series Research Projects><R01 Mechanism><R01 Program><Research><Research Grants><Research Project Grants><Research Projects><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Secure><Severe acute respiratory syndrome coronavirus 2><Severities><Severity of illness><Therapeutic><Vaccines><Virus><Woman><Wuhan coronavirus><adulthood><age 18 years><base><bio-markers><biologic marker><biomarker><biomarker discovery><clinical research site><clinical site><cohort><corona virus><corona virus disease><corona virus disease 2019><coronavirus disease><coronavirus disease 2019><coronavirus emergence><design><designing><disease severity><eighteen year old><eighteen years of age><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><enroll><experience><heavy metal Pb><heavy metal lead><host response><immunophenotype><immunoresponse><interventional strategy><nCoV><new CoV><new coronavirus><new diagnostics><next generation diagnostics><novel CoV><novel coronavirus><novel diagnostics><pandemic><pandemic disease><prevent><preventing><prognostic><recruit><research study><respiratory>